Drug General Information (ID: DDIVK3OSGX)
  Drug Name Mazindol Drug Info Tranylcypromine Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Cns Stimulants Antidepressants
  Structure

 Mechanism of Mazindol-Tranylcypromine Interaction (Severity Level: Major)
     Additive hypertensive effects Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Mazindol Tranylcypromine
      Mechanism 1 Hypertensive effects Hypertensive effects
      Key Mechanism Factor 1
Factor Name Hypertensive effects
Factor Description Hypertension is defined as a blood pressure reading above a prescribed limit (130/90 mmHg). Most people with hypertension have no signs or symptoms; others may experience: severe headache, shortness of breath, nosebleeds, severe anxiety, and feeling a tingling sensation in the neck or head.
      Mechanism Description
  • Additive hypertensive effects by the combination of Mazindol and Tranylcypromine 
     Increased risk of hyperpyrexia Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Mazindol Tranylcypromine
      Mechanism 2 Hyperpyrexia Hyperpyrexia
      Key Mechanism Factor 2
Factor Name Hyperpyrexia
Factor Description Hyperthermia is an extreme, life-threatening increase in core body temperature. If hyperthermia persists for a long time or worsens, more serious symptoms may occur, such as confusion, headache, constricted pupils, vomiting, diarrhea, and decreased urine output.
      Mechanism Description
  • Increased risk of hyperpyrexia by the combination of Mazindol and Tranylcypromine 

Recommended Action
      Management In general, CNS stimulants should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine).

References
1 Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5. [PMID: 4685619]
2 Markowitz JS, Patrick KS "Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder." Clin Pharmacokinet 40 (2001): 753-72. [PMID: 11707061]
3 Product Information. Adderall (amphetamine-dextroamphetamine) Shire Richwood Pharmaceutical Company, Florence, KY.